Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 8/20 | 0.61 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543631 | 0.91 | ALDH1A1 (0.50) | CDC7DBF4CCNE1CDK2ADORA2A | |
| SCHEMBL544650 | 0.83 | ALOX5 (0.55) | CDC7DBF4CCNE1CDK2ADORA2A | |
| SCHEMBL11652829 | 0.81 | ALOX5 (0.54) | ADORA2AADORA1KDM4ERAB9AKMT2A | |
| SCHEMBL14148598 | 0.81 | KDM4E (0.57) | ADORA2AADORA1KDM4EKMT2ANOTUM | |
| SCHEMBL14148757 | 0.81 | PTGDR2 (0.57) | CDC7DBF4CCNE1CDK2ADORA2A | |
| SCHEMBL14148616 | 0.81 | DPP4 (0.50) | CDC7DBF4CCNE1CDK2ADORA2A | |
| SCHEMBL11456658 | 0.81 | CDC7 (0.67) | CDC7DBF4CCNE1CDK2ADORA2A | |
| SCHEMBL66549 | 0.79 | CDC7 (0.60) | CDC7DBF4CCNE1CDK2IDO1 | |
| SCHEMBL14148755 | 0.78 | PTGDR2 (0.60) | ADORA2AADORA1KDM4ENPC1RAB9A | |
| SCHEMBL14148648 | 0.78 | PTGDR2 (0.60) | ADORA2AADORA1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| CN-101035802-A | Inhibitors of IAP | GENENTECH INC (US) | 2007-09-12 | — | — | CN | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1778718-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014361-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | CDC7 1668/4885DBF4 1890/4885CCNE1 1254/4885 |
| US-20120202750-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | CDC7 1668/4885DBF4 1890/4885CCNE1 1254/4885 |
| US-20060014700-A1 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | BIRC5, BIRC2, XIAP | CDC7 1414/4885DBF4 3621/4885CCNE1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.